These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33262074)

  • 1. In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.
    Ferrari V; Tarke A; Fields H; Ferrari L; Conley T; Ferrari F; Koşaloğlu-Yalçın Z; Sette A; Peters B; McCarthy CL; Bashey A; Tzachanis D; Ball ED; Tanaka TN; Bejar R; Lane TA; Vitiello A
    Cytotherapy; 2021 Apr; 23(4):320-328. PubMed ID: 33262074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of U2AF1 neoantigens in myeloid neoplasms.
    Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome.
    Tanaka TN; Ferrari V; Tarke A; Fields H; Ferrari L; Ferrari F; McCarthy CL; Sanchez AP; Vitiello A; Lane TA; Bejar R
    Cytotherapy; 2021 Mar; 23(3):236-241. PubMed ID: 33279399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.
    Blaeschke F; Paul MC; Schuhmann MU; Rabsteyn A; Schroeder C; Casadei N; Matthes J; Mohr C; Lotfi R; Wagner B; Kaeuferle T; Feucht J; Willier S; Handgretinger R; StevanoviĆ S; Lang P; Feuchtinger T
    Cytotherapy; 2019 Sep; 21(9):973-986. PubMed ID: 31351799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
    Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
    Front Immunol; 2020; 11():373. PubMed ID: 32226429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
    Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
    Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse Neoantigens and the Development of Cancer Therapies.
    Srivastava RM; Purohit TA; Chan TA
    Semin Radiat Oncol; 2020 Apr; 30(2):113-128. PubMed ID: 32381291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A liposomal RNA vaccine inducing neoantigen-specific CD4
    Salomon N; Vascotto F; Selmi A; Vormehr M; Quinkhardt J; Bukur T; Schrörs B; Löewer M; Diken M; Türeci Ö; Sahin U; Kreiter S
    Oncoimmunology; 2020 Jun; 9(1):1771925. PubMed ID: 32923128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen prediction.
    Chuwdhury GS; Guo Y; Chiang CL; Lam KO; Kam NW; Liu Z; Dai W
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing neoantigen-targeted T cell-based treatments for solid tumors.
    Yamamoto TN; Kishton RJ; Restifo NP
    Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
    Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
    J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies.
    Kast F; Klein C; Umaña P; Gros A; Gasser S
    Oncoimmunology; 2021 Jan; 10(1):1869389. PubMed ID: 33520408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.